Effects of recombinant human growth hormone on fat distribution in patients with human immunodeficiency virus-associated wasting.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 12410487.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In light of current interest in recombinant human growth hormone (GH) as a treatment for fat distribution abnormalities, we retrospectively evaluated regional changes in fat and lean body mass in a subset of subjects who participated in randomized, double-blind, placebo-controlled trials of GH for treatment of wasting. Treatment with a pharmacologic dose of GH (0.1 mg/kg/day) resulted in significant and sustained increases in lean body mass and losses of fat in both the trunk and appendicular regions.
Medical subject headings
- Fats
- HIV Infections
- Human Growth Hormone
- Metabolic Diseases